.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Argus Health
Medtronic
Dow
Colorcon
Mallinckrodt
Moodys
Harvard Business School
US Army

Generated: September 25, 2017

DrugPatentWatch Database Preview

J And J Consumer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for J AND J CONSUMER INC, and when can generic versions of J AND J CONSUMER INC drugs launch?

J AND J CONSUMER INC has twenty-eight approved drugs.

There are nine US patents protecting J AND J CONSUMER INC drugs.

There are one hundred and eleven patent family members on J AND J CONSUMER INC drugs in forty-three countries.

Summary for Applicant: J And J Consumer Inc

Patents:9
Tradenames:22
Ingredients:10
NDAs:28
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc
ZYRTEC HIVES RELIEF
cetirizine hydrochloride
TABLET;ORAL019835-005Nov 16, 2007OTCYesNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC HIVES RELIEF
cetirizine hydrochloride
TABLET;ORAL019835-006Nov 16, 2007OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
MOTRIN IB
ibuprofen
TABLET;ORAL019012-003Dec 17, 1990OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
TYLENOL
acetaminophen
TABLET, EXTENDED RELEASE;ORAL019872-001Jun 8, 1994OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-002Dec 17, 2007OTCYesYes► Subscribe► SubscribeY► Subscribe
J And J Consumer Inc
CHILDREN'S ZYRTEC ALLERGY
cetirizine hydrochloride
SYRUP;ORAL022155-002Nov 16, 2007OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET;ORAL021140-001Nov 30, 2000OTCYesYes► Subscribe► SubscribeY ► Subscribe
J And J Consumer Inc
SINE-AID IB
ibuprofen; pseudoephedrine hydrochloride
TABLET;ORAL019899-001Dec 31, 1992OTCNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM A-D
loperamide hydrochloride
SUSPENSION;ORAL019487-002Jul 8, 2004OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC-D 12 HOUR
cetirizine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021150-002Nov 9, 2007OTCYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for J And J Consumer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
J And J Consumer Inc
TYLENOL
acetaminophen
TABLET, EXTENDED RELEASE;ORAL019872-001Jun 8, 1994► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM A-D
loperamide hydrochloride
SOLUTION;ORAL019487-001Mar 1, 1988► Subscribe► Subscribe
J And J Consumer Inc
PEPCID COMPLETE
calcium carbonate; famotidine; magnesium hydroxide
TABLET, CHEWABLE;ORAL020958-001Oct 16, 2000► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET;ORAL020325-001Apr 28, 1995► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET, CHEWABLE;ORAL020606-001Jun 26, 1996► Subscribe► Subscribe
J And J Consumer Inc
CHILDREN'S MOTRIN
ibuprofen
TABLET, CHEWABLE;ORAL020601-001Nov 15, 1996► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC
cetirizine hydrochloride
SYRUP;ORAL020346-001Sep 27, 1996► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET;ORAL021140-001Nov 30, 2000► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC-D 12 HOUR
cetirizine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021150-002Nov 9, 2007► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET;ORAL020902-001Aug 5, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for J AND J CONSUMER INC drugs

Drugname Dosage Strength Tradename Submissiondate
cetirizine hydrochloride
Syrup5 mg/5 mL
ZYRTEC
3/19/2007
cetirizine hydrochloride
Chewable Tablets5 mg and 10 mg
ZYRTEC
3/25/2005
calcium carbonate/ famotadine/ magnesium hydroxide
Chewable Tablets800 mg/ 10 mg/ 165 mg (OTC)
PEPCID COMPLETE
11/1/2004

Non-Orange Book Patents for J And J Consumer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,060,730Rapidly absorbed liquid compositions► Subscribe
6,489,329 Pharmaceutical compositions for the treatment of rhinitis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for J And J Consumer Inc Drugs

Country Document Number Estimated Expiration
China1520285► Subscribe
China1261799► Subscribe
Peru42598► Subscribe
Hungary0400386► Subscribe
Russian Federation2192863► Subscribe
Austria259236► Subscribe
Argentina013227► Subscribe
Japan2007176958► Subscribe
Slovenia1404304► Subscribe
El Salvador1997000026► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for J And J Consumer Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
01C/045Belgium► SubscribePRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
2008006,C0933372Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
C/GB98/013United Kingdom► SubscribePRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
2014 00050Denmark► SubscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Harvard Business School
UBS
Medtronic
Boehringer Ingelheim
Chubb
Moodys
Covington
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot